185 related articles for article (PubMed ID: 20171660)
1. Editorial comment.
Wood CG
J Urol; 2010 Apr; 183(4):1315-6; discussion 1316. PubMed ID: 20171660
[No Abstract] [Full Text] [Related]
2. Editorial comment on: Prognostic value of capsular invasion for localized clear-cell renal cell carcinoma.
Volpe A
Eur Urol; 2009 Dec; 56(6):1012. PubMed ID: 19135777
[No Abstract] [Full Text] [Related]
3. Editorial comment.
Kattan MW
Urology; 2010 Jun; 75(6):1371; author reply 1371-2. PubMed ID: 20513496
[No Abstract] [Full Text] [Related]
4. Editorial comment.
Klatte T
J Urol; 2009 Nov; 182(5):2136. PubMed ID: 19758634
[No Abstract] [Full Text] [Related]
5. Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.
Eggener S
Eur Urol; 2010 Mar; 57(3):472. PubMed ID: 19359087
[No Abstract] [Full Text] [Related]
6. Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.
Russo P
Eur Urol; 2010 Mar; 57(3):472-3. PubMed ID: 19359086
[No Abstract] [Full Text] [Related]
7. Editorial comment on: Prognosis value of renal vein and inferior vena cava involvement in renal cell carcinoma.
Russo P
Eur Urol; 2009 Feb; 55(2):459. PubMed ID: 18692952
[No Abstract] [Full Text] [Related]
8. Editorial comment on: Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
Kirkali Z
Eur Urol; 2009 Feb; 55(2):460. PubMed ID: 18692949
[No Abstract] [Full Text] [Related]
9. Editorial comment.
Klatte T
J Urol; 2009 Dec; 182(6):2606. PubMed ID: 19836796
[No Abstract] [Full Text] [Related]
10. Editorial comment.
Pantuck AJ
J Urol; 2010 Mar; 183(3):914. PubMed ID: 20083263
[No Abstract] [Full Text] [Related]
11. Editorial comment.
Russo P
Urology; 2010 Feb; 75(2):275-6; author reply 276. PubMed ID: 20152477
[No Abstract] [Full Text] [Related]
12. Editorial comment.
Pomara G; Francesca F
Urology; 2011 May; 77(5):1146; author reply 1146-7. PubMed ID: 21539964
[No Abstract] [Full Text] [Related]
13. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Blute ML
Eur Urol; 2010 Jan; 57(1):110-1. PubMed ID: 19062158
[No Abstract] [Full Text] [Related]
14. Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Giannarini G; Autorino R
Eur Urol; 2010 Jan; 57(1):109-10. PubMed ID: 19062156
[No Abstract] [Full Text] [Related]
15. Editorial comment.
Campbell SC; Lane BR
J Urol; 2010 Feb; 183(2):485; discussion 485. PubMed ID: 20006871
[No Abstract] [Full Text] [Related]
16. Editorial comment.
Uzzo RG
J Urol; 2009 Nov; 182(5):2171. PubMed ID: 19758642
[No Abstract] [Full Text] [Related]
17. Editorial comment.
Russo P
Urology; 2009 May; 73(5):1082. PubMed ID: 19394510
[No Abstract] [Full Text] [Related]
18. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
Billis A
Int Braz J Urol; 2004; 30(4):347-8. PubMed ID: 15679982
[No Abstract] [Full Text] [Related]
19. The use of simplified versions of the Fuhrman nuclear grading system in clinical practice requires the agreement of a multidisciplinary panel of experts.
Ficarra V; Novara G; Martignoni G
Eur Urol; 2009 Nov; 56(5):782-4; discussion 784-5. PubMed ID: 19660853
[No Abstract] [Full Text] [Related]
20. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Novara G
Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
[No Abstract] [Full Text] [Related]
[Next] [New Search]
